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Abstract
Background: Increased uric acid is associated with the
metabolic syndrome, conditions linked to oxidative stress
and insulin resistance. Non-alcoholic fatty liver disease
(NAFLD) is now considered a hepatic manifestation of insu-
lin resistance. However, little has been written regarding the
association between uric acid and NAFLD.
Methods: We examined the association between uric acid
and the presence of NAFLD in 3768 Koreans (2133 men,
1635 women; aged 20–75 years) in a health examination
program. Uric acid quartiles were categorized separately as
follows: Q1: F291.5, Q2: 291.6–333.1, Q3: 333.2–380.7,
and Q4: G380.8 mmol/L for men; Q1: F202.2, Q2:
202.3–232.0, Q3: 231.1–267.7, and Q4: G267.8 mmol/L for
women. Hepatic steatosis was diagnosed based on abdominal
ultrasonographic findings by hyperechogenicity of liver tis-
sue, difference of echogenicity between the liver and dia-
phragm, and visibility of vascular structures. The odds ratios
(ORs) and 95% confidence intervals (CIs) for NAFLD were
calculated across each quartile of serum uric acid.
Results: The prevalence of NAFLD was 25.8% (32.2% in
men and 17.4% in women). After adjustment for age, body
mass index (BMI), smoking, regular exercise, blood pressure,
fasting plasma glucose (FPG), triglycerides, and high-density
lipoprotein (HDL) cholesterol, the ORs (95% CIs) for
NAFLD according to each quartile of uric acid were 1.00,
1.55 (1.13–2.14), 1.77 (1.30–2.41), and 2.01 (1.45–2.78) for
men and 1.00, 0.69 (0.40–1.20), 1.12 (0.67–1.88), and 1.94
(1.21–3.13) for women.
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Conclusions: Serum uric acid is independently associated
with the presence of NAFLD, and uric acid may be a useful
additional measure in assessing the risk of NAFLD in the
clinical setting.
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Introduction
Uric acid is the major end product of purine metabolism and
is formed from xanthine by the action of xanthine oxidore-
ductase (1). Serum uric acid concentrations have long been
considered a marker of gout or urolithiasis. However, emerg-
ing evidence suggests that increased uric acid, despite being
a major antioxidant in the human plasma (2), is associated
with the prevalence and incidence of cardiovascular disease
(CVD) (3), diabetes (4) and metabolic syndrome (5, 6), con-
ditions linked to increased oxidative stress, chronic low-
grade inflammation, and insulin resistance (7, 8).
Non-alcoholic fatty liver disease (NAFLD) is defined as
a diffuse accumulation of fat in the liver, after excluding
excessive alcohol intake and other causes of liver disease.
NAFLD has clinical implications because of its increasing
prevalence worldwide and its potential to progress to
advanced cirrhosis and hepatic failure (9, 10). Along with
the ‘‘obesity epidemic’’, the worldwide prevalence of
NAFLD, based on imaging studies, is increasing rapidly and
now includes 14%–31% of the general population (11). It is
generally attributed to obesity-induced insulin resistance.
The development of NAFLD is closely associated with the
metabolic syndrome and the association between serum uric
acid concentration and metabolic syndrome has been dem-
onstrated in previous studies (10, 11), which leads us to spec-
ulate that there might be a relationship between uric acid
concentrations and NAFLD. Although several laboratory
parameters, such as alanine aminotransferase (ALT), the
homeostasis model assessment of insulin resistance (HOMA-
IR) index, and C-reactive protein (CRP) have been reported
as useful markers for the diagnosis of NAFLD (12, 13), little
has been written regarding the association between uric acid
and NAFLD. Therefore, we performed a cross-sectional
study to examine whether serum uric acid concentrations are
related to NAFLD as determined by abdominal ultrasono-
graphy in 3768 Korean adults (2133 men, 1635 women; ages
20–75 years) from the health risk assessment study
(HERAS) cohort.
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Materials and Methods
Study population
The HERAS cohort consisted of 5342 subjects (2347 men and 2995
women) who voluntarily visited the Health Promotion Center, Gang-
nam Severance Hospital, Seoul, Korea, for a routine health check
up between March 2006 and May 2007. Because Koreans are a
group of East Asians with ethnic homogeneity and lower body mass
index (BMI) compared to Westerners, different ethnicity and life-
style factors of Koreans may affect CVD risk factors in different
ways. This cohort was used to characterize the ethnic specific CVD
risk factors and explore surrogate markers for CVD in Korean adults
(14, 15). This study was approved by the Institutional Review Board
of Yonsei University College of Medicine, Seoul, Korea. The cur-
rent analysis was limited to the 4365 subjects who received abdom-
inal ultrasonography. Subjects meeting any of the following criteria
were excluded: subjects with any missing covariate information;
subjects with an alcohol intake of 140 g/week or more for men and
70 g/week or more for women; a positive test for hepatitis B anti-
gens or hepatitis C antibodies; serum creatinine G123.7 mmol/L; a
history of cancer, respiratory, renal, hepatobiliary, gout, and other
rheumatologic disease. After exclusions, 3768 subjects (2133 men,
1635 women; ages 20–75 years) were included in the final analysis.
Data collection
Self reported cigarette smoking, alcohol consumption, and physical
activity were determined using questionnaires. Smoking status was
categorized as non-smokers, ex-smokers, and current smokers.
Questions regarding alcohol intake included the type of alcoholic
beverage, frequency, and amount of alcohol consumed on a weekly
basis. Participants were asked about the type and frequency of phys-
ical activity performed weekly. Medical examinations were per-
formed by trained medical staff using a standardized procedure.
Body weight and height were measured in subjects wearing light
indoor clothing and without shoes to the nearest 0.1 kg and 0.1 cm,
respectively. BMI was calculated as the ratio of weight (kg) to
height (m2). Following a 12-h overnight fast, blood samples were
obtained from the antecubital vein of each subject. High-sensitivity
C-reactive protein (hsCRP) concentrations were measured using the
Roche/Hitachi 912 System (Roche Diagnostics, Indianapolis, IN,
USA) and a latex-enhanced immunoturbidimetric method with a
lower limit of detection of 0.02 (mg/L). Fasting plasma glucose
(FPG), total cholesterol, triglycerides, high-density lipoprotein
(HDL) cholesterol, aspartate aminotransferase (AST), ALT, g-glu-
tamyltransferase (GGT), and uric acid were measured by enzymatic
methods using the Hitachi 7600-110 automated chemistry analyzer
(Hitachi, Tokyo, Japan). The upper laboratory reference limit for
uric acid concentrations were 475.8 mmol/L for men and
321.2 mmol/L for women. Diabetes was defined as a self-reported
history of the disorder or a FPG G7.0 mmol/L. Hypertension was
defined as a self-reported history of the disorder, systolic blood
pressure (SBP) G140 mm Hg, or diastolic blood pressure (DBP)
G90 mm Hg.
Because liver biopsy in apparently healthy subjects is not ethical
and the sample size was very large, a diagnosis of fatty liver was
based on abdominal ultrasonography with a 3.5-MHz transducer
(HDI 5000, Philips, Bothell, USA). Ultrasonography was performed
by two experienced radiologists who were unaware of the goals of
the study and blinded to laboratory findings. The presence and
severity of hepatic steatosis was classified into three groups, grade
1 (mild), grade 2 (moderate), and grade 3 (severe) according to the
hyperechogenicity of liver tissue, difference of echogenicity
between the liver and diaphragm, and visibility of vascular struc-
tures (16). Liver with any degree of hepatic steatosis was considered
fatty in the present study. The modified National Cholesterol Edu-
cation Program Adult Treatment Panel III (NCEP-ATP III) was used
for the definition of metabolic syndrome. Because waist circumfer-
ence was not measured, we defined the diagnosis of obesity as a
BMI G25 kg/m2 as suggested by the position statement of Amer-
ican College of Endocrinology (17). Therefore, metabolic syndrome
was defined by the presence of three or more of the following risk
factors: 1) obesity with BMI G25.0 kg/m2, 2) high triglycerides
G1.70 mmol/L, 3) low HDL cholesterol -1.04 mmol/L for men
and -1.30 mmol/L for women, 4) increased SBP G130 mm Hg
or increased DBP G85 mm Hg, and 5) and high FPG G 6.1 mmol/
L. Subjects who reported taking anti-hypertensive or antidiabetic
medication were considered to have increased blood pressure or
high FPG, respectively.
Statistical analysis
Because uric acid concentrations differ significantly by gender, uric
acid quartiles were categorized separately as follows: Q1: F291.5,
Q2: 291.6–333.1, Q3: 333.2–380.7, and Q4: G380.8 mmol/L for
men; Q1: F202.2, Q2: 202.3–232.0, Q3: 231.1–267.7, and Q4:
G267.8 mmol/L for women. The basic characteristics of the study
population according to uric acid quartiles were compared using a
one way analysis of variance (ANOVA) or Kruskal-Wallis test for
continuous variables, and x2-test for categorical variables. The odds
ratios (ORs) and 95% confidence intervals (95% CIs) for NAFLD
were calculated after adjusting for confounding variables across
each quartile of serum uric acid concentration using multivariate
logistic regression analysis. All analyses were conducted using SAS
statistical software, version 9.1 (SAS Institute Inc., Cary, NC, USA).
All statistical tests were two-sided and a p-0.05 was used for sta-
tistical significance.
Results
Table 1 shows the characteristics of the 2133 men and 1635
women. The mean age for men was 46.5"10.2 years and
45.5"11.0 years for women. The mean BMI (kg/m2) was
24.6 for men and 22.8 for women. Mean uric acid concen-
trations (mmol/L) were 339.0 for men and 237.9 for women.
39.1% of men and 5.4% of women were current smokers,
and the proportion of those with metabolic syndrome was
23.8% for men and 15.4% for women.
The demographic and biochemical characteristics of the
study population in relation to serum uric acid concentrations
are also shown in Table 2. The mean BMI, SPB and DBP,
FPG, total cholesterol, triglycerides, AST, ALT, and GGT
were highest in the 4th quartile for uric acid in both men
and women, whereas HDL cholesterol concentration was
lowest in the 4th quartile. The geometric mean values of
hsCRP concentrations were highest in the 4th quartile of uric
acid in both men and women. The proportion of hyperten-
sion, diabetes, and metabolic syndrome was the highest in
the 4th quartile for both genders.
Figure 1 shows the mean values of uric acid according to
the grade of hepatic steatosis. Uric acid increased according
to the grade of hepatic steatosis: 327.4, 349.5, 362.5, and
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375.9 mmol/L in men, and 235.3, 257.8, 274.0, and
314.9 mmol/L in women with normal, mild, moderate, severe
fatty liver, respectively.
Table 2 shows the risk of NAFLD in terms of uric acid
quartiles. After adjustment for age, BMI, cigarette smoking,
regular exercise, total cholesterol, triglycerides, and HDL
cholesterol, the adjusted OR (95% CI) for the highest vs. the
lowest quartile of uric acid was 2.01 (1.45–2.78) in men.
Among women, the prevalence risk of NAFLD was 1.94
(1.21–3.13), after adjustment for the same variables. We also
assessed the association between serum uric acid concentra-
tion and risk of NAFLD after additional adjustments for liver
enzymes and hsCRP concentrations. These associations were
similar after using model 3 (Table 2).
Discussion
NAFLD is now recognized worldwide as an important cause
of chronic liver disease. The prevalence of NAFLD in this
study was 25.8% (32.2% in men and 17.4% in women),
which was similar to the data from the general population in
Italy (23%) (18), Israel (30%) (19) and Japan (29%) (20).
In multivariate logistic regression analysis, we observed
independent associations between serum uric acid concentra-
tions and the presence of NAFLD. These associations
remained even after adjustment for other surrogate markers
of NAFLD, such as AST, ALT, GGT and hsCRP through
model 3 (Table 2). These findings indicate that the serum
uric acid concentration may be closely related with NAFLD,
independent of markers of liver injury and inflammation.
Our results are in agreement with previous studies. Serum
uric acid was independently associated with biopsy-proven
hepatic steatosis in a study of 1915 Chinese patients aged
12–80 years with chronic hepatitis B infection (21). Li et al.
(22) also reported similar results in a study of 8925 (6802
men) apparently healthy Chinese. However, in that study,
gender difference was not fully considered since separate
data for both gender using multivariate analysis was not per-
formed. As shown in the present study, there is a significant
gender difference in the distribution of uric acid. Our study
showed that these associations between serum uric acid con-
centration and NAFLD can be applied to both men and wom-
en through gender-specific multivariate logistic regression
analysis.
Some mechanisms could explain the significant relation-
ships between serum uric acid and NAFLD. Current under-
standing of the progression of NAFLD involves the ‘‘2-hits
hypothesis’’ (12). The ‘‘first hit’’ is excessive fat accumu-
lation in hepatocytes, which is closely linked to insulin resis-
tance. As mentioned previously, NAFLD is now considered
a hepatic manifestation of insulin resistance. Numerous stud-
ies have introduced significant associations between serum
uric acid concentrations and the metabolic syndrome and its
components (5, 6), where insulin resistance is the primary
problem.
Serum uric acid concentrations were associated signifi-
cantly with the degree of hepatic steatosis in our study (Fig-
ure 1). These findings are consistent with current knowledge
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Figure 1 Mean values of uric acid according to the grade of hepatic steatosis (normal, mild, moderate, and severe fatty liver) in both men
and women.
regarding the association between serum uric acid concen-
trations and insulin resistance and the metabolic syndrome
(23). Thus, the significant association between serum uric
acid and NAFLD suggest that insulin resistance is a possible
mechanism linking uric acid with NAFLD. Despite the sig-
nificant relationship between uric acid and NAFLD in the
present study, it cannot be concluded whether serum uric acid
concentration is a risk factor actively involved in the devel-
opment of NAFLD. It could be a consequence of NAFLD
(24, 25). Because this study is of cross-sectional design,
causal relationships cannot be determined, warranting pro-
spective studies.
The ‘‘second hit’’ is the process from oxidative stress to
hepatocyte injury, inflammation and fibrosis. Excessive free
fatty acids (FFA) in hepatocytes of patients with NAFLD
generate an excess of reactive oxygen species (ROS) leading
to lipid peroxidation of hepatocyte, cytokine production, and
hepatic inflammation (12).
An experimental study has shown that uric acid stimulates
the synthesis of monocyte chemoattractant protein-1, inter-
leukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis fac-
tor-a (TNF-a) (26), all of which are proinflammatory
molecules and stimulate production of CRP in the liver (27).
Ruggiero et al. (28) have also shown that uric acid is sig-
nificantly and independently associated with inflammatory
markers, such as CRP, IL-6, IL-18, and TNF-a in Italian
men. The significant associations between uric acid and
hsCRP in the present study also support the concept that uric
acid may be involved in oxidative stress and systemic
inflammation. In this regard, major factors connecting
increased serum uric acid concentration with NAFLD may
be oxidative stress and chronic low-grade inflammation. Sev-
eral prospective studies also have linked uric acid with a
potential risk factor for CVD, stroke, and diabetes (3–5),
where the underlying mechanisms were closely linked to an
excess of oxidative stress and chronic low-grade inflamma-
tion (7–9).
Our study has several limitations. First, because study sub-
jects were volunteers visiting for health promotion screening
in single hospital and appeared to be slightly healthier indi-
viduals compared to community-based cohorts, the study
population may not be representative of the general popu-
lation in Korea. Therefore, this study may have been affected
by selection bias. Second, we did not take into consideration
the effect of other potential confounding variables on uric
acid concentration, e.g., diet pattern, a history of medications
with hyperuricemic activity (diuretics or beta-blockers). The
Framingham heart study showed that use of diuretics was a
major confounder in the relationship between uric acid con-
centrations and mortality risk (29), but we could not consider
these effects on abnormal uric acid concentrations. Third,
central obesity indicated by waist circumference rather than
BMI is more likely to be associated with metabolic syndrome
and NAFLD (18). We used BMI instead of waist circumfer-
ence as a component of metabolic syndrome and as a con-
founding variable in multivariate logistic regression model,
not only because waist circumference was not measured at
the beginning of this study, but also because BMI has already
been shown to be associated with NAFLD in previous stud-
ies (19, 20). Finally, although liver biopsy is the gold stan-
dard for the diagnosis of fatty liver, biopsy-proven NAFLD
was not performed in the present study. However, liver biop-
sy is an invasive and impractical procedure in the standard
clinical setting. Ultrasonography is a non-invasive and wide-
ly available method for qualitative assessment of fatty infil-
tration. Thus, ultrasonography is the preferred modality for
mass screening for hepatic steatosis and has reasonable sen-
sitivity (up to 94%) and specificity (up to 84%) (30).
In summary, increased uric acid concentrations are inde-
pendently associated with the presence of NAFLD. Our find-
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ings indicate that increased uric acid concentrations may be
a useful additional measure in assessing the risk of NAFLD
in the clinical setting. Further research is warranted to better
understand its pathophysiologic role in the development of
NAFLD.
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